• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>BMJ Case Reports >Double-edged sword effect of anticoagulant in COVID-19 infection
【2h】

Double-edged sword effect of anticoagulant in COVID-19 infection

机译：Covid-19感染抗凝血剂的双刃剑作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Coagulation predominant-type coagulopathy such as microthrombosis and macrothrombosis is a well-known recognised complication found in COVID-19 infected critically ill patients. In the context of high incidence of thrombotic events in patients with COVID-19, supplementation with anticoagulant therapy has been routinely recommended and shown to reduce mortality. However, the recommended type, dose, duration and timing of anticoagulant has not been determined yet. Spontaneous retroperitoneal haematoma secondary to anticoagulant therapy is one of the well-known but self-limiting conditions. We report a 51-year-old COVID-19 positive woman, who was taking intermediate-intensity heparin therapy for venous thromboembolism prophylaxis and died from complication of retroperitoneal bleeding. Further studies are needed to verify the risk–benefit ratio of anticoagulant therapy in patients with COVID-19. Although anticoagulant deems appropriate to use in patients with COVID-19, clinicians should be cautious about major bleeding complication such as retroperitoneal haemorrhage even when full therapeutic dosage is not used.
机译：凝血优势型凝结病如微生物结晶和宏张相形，是在Covid-19感染的危重病患者中发现的众所周知的公认并发症。在Covid-19患者血栓形成事件的高发生率的背景下，补充抗凝治疗的补充已经常规推荐并显示降低死亡率。然而，抗凝血剂的推荐类型，剂量，持续时间和时序尚未确定。第二次抗凝血治疗的自发腹膜血肿是众所周知但自我限制的条件之一。我们举报了一个51岁的Covid-19正面妇女，他正在服用中间强度肝素治疗，用于静脉血栓栓塞预防，并从腹膜后出血并发症中死亡。需要进一步的研究来验证Covid-19患者抗凝治疗的风险效益比。虽然抗凝血剂认为适合使用Covid-19患者，但临床医生应该对主要出血并发症如腹膜后的复制，即使不使用完整的治疗剂量也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号